NBP on Nasdaq

NovaBridge Biosciences

Pharmaceutical preparations company in the Cayman Islands.

Price unavailable

Last updated Oct 18, 2026.

Overview

-$46.3MNet income, fiscal 20252

Compare with BioXcel Therapeutics, Inc., Polomar Health Services, Inc. or Karuna Therapeutics, or pick any stock.

  • TickerNBP on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersE9
  • Incorporated inCayman Islands3
  • Business addressSuite 400, 2440 Research Blvd, Rockville, Md 208503
  • Filer categoryNon-accelerated filer3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-11395.1%Operating margin2
-32868.5%Net margin2
-140.7%Revenue growth, 20232
-85.6%Return on equity2
-$184.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$21.4M
  • Interest0¢$102.0K

Out of $632.0K in revenue.2 The company lost money this year.

Financial statements

Revenue56782$632.0K in 2023−85% since 2019
-$100.0M0$100.0M$200.0M$300.0M2019: $4.3M$4.3M20192020: $236.4M$236.4M2020+5387%2021: $13.8M$13.8M2021−94%2022: -$1.6M-$1.6M20222023: $632.0K$632.0K2023
Operating income82-$72.0M in 2023+36% since 2022
-$80.0M-$60.0M-$40.0M-$20.0M02022: -$53.1M-$53.1M20222023: -$72.0M-$72.0M2023+36%
Net income56782-$207.7M in 2023−0% since 2019
-$400.0M-$200.0M0$200.0M2019: -$208.6M-$208.6M20192020: $72.2M$72.2M20202021: -$365.9M-$365.9M20212022: -$371.1M-$371.1M2022+1%2023: -$207.7M-$207.7M2023−44%
Fiscal year201820192020202120222023
Revenue$4.3M5$236.4M6$13.8M7-$1.6M8$632.0K2
Cost of revenue$7.3M7$3.9M9
Research and development$120.7M5$150.9M6$190.3M7$22.5M8$21.4M2
Operating income-$53.1M8-$72.0M2
Interest$430.0K5$147.0K6$07$1.0K9$102.0K4
Income tax$1.9M6-$495.0K7$103.0K8$02
Net income-$208.6M5$72.2M6-$365.9M7-$371.1M8-$207.7M2
Earnings per share-$28.905$0.546-$2.097-$1.968-$1.092
Earnings per share (diluted)-$28.905$0.466-$2.097-$1.968-$1.092

Compare NovaBridge Biosciences with another company

Leadership

Who has led NovaBridge Biosciences, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Srishti Gupta2026–now

Chief financial officer

  1. Ming Kyler Lei2026–now
Board members and other officers (20)

Former names

  • I-MabJul 29, 2019 to Oct 28, 20253

Timeline

  1. Jul 8, 2026New chief executive Srishti Gupta becomes CEO10

Filings

221 filings to the SEC since October 2021: 6 annual reports, 36 insider forms, 18 large holders, 161 other. The latest 20:

  1. Oct 13, 20266-K EDGAR
  2. Sep 21, 20264 EDGAR
  3. Sep 18, 2026144 EDGAR
  4. Sep 11, 20264 EDGAR
  5. Sep 10, 20263 EDGAR
  6. Sep 9, 2026144 EDGAR
  7. Sep 8, 20264 EDGAR
  8. Sep 8, 20266-K EDGAR
  9. Sep 8, 20266-K EDGAR
  10. Sep 1, 20264 EDGAR
  11. Aug 25, 20264 EDGAR
  12. Aug 20, 20266-K EDGAR
  13. Aug 20, 20266-K EDGAR
  14. Aug 17, 2026S-8 EDGAR
  15. Jul 24, 20266-K EDGAR
  16. Jul 17, 20266-K EDGAR
  17. Jul 10, 20264 EDGAR
  18. Jul 10, 20264 EDGAR
  19. Jul 8, 20264 EDGAR
  20. Jul 8, 20263 EDGAR

The 221 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 18 such filings since October 2021, the latest 10:

  1. Feb 3, 2026SCHEDULE 13D/A
  2. Aug 7, 2025SCHEDULE 13D/A
  3. Aug 5, 2025SCHEDULE 13D
  4. Feb 5, 2025SCHEDULE 13D
  5. Feb 13, 2024SC 13G/A
  6. Feb 9, 2024SC 13G/A
  7. Feb 6, 2024SCHEDULE 13G
  8. Dec 1, 2023SC 13D
  9. Jun 30, 2023SC 13D/A
  10. Feb 15, 2023SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 49. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Hhlr Advisors, Ltd.5,980,568$11.7M1.4%No change
Morgan Stanley3,653,228$7.1M0.0%−184,970
AIHC Capital Management Ltd2,878,033$5.6M5.4%+615,100
Siren, L.L.C.2,004,739$3.9M0.1%−995,261
Marshall Wace, Llp1,231,946$2.4M0.0%New
Candriam S.C.A.1,132,563$2.2M0.0%No change
Adage Capital Partners Gp, L.l.c.1,000,000$1.9M0.0%No change
Two Sigma Investments, LP851,348$1.7M0.0%New
Renaissance Technologies LLC758,226$1.5M0.0%+485,814
BlackRock, Inc.686,208$1.3M0.0%+58,712
Citadel Advisors LLC622,831$1.2M0.0%+456,215
E Fund Management Co., Ltd.589,020$1.1M0.0%New
Exome Asset Management LLC576,960$1.1M0.7%No change
State Street Corp360,376$702.7K0.0%−9,731
Woodline Partners LP350,000$682.5K0.0%−350,000
Fiera Capital Corp315,681$615.6K0.0%No change
UBS Group AG301,780$588.5K0.0%+238,239
Barclays PLC279,019$544.1K0.0%−20,280
Taikang Asset Management (Hong Kong) Co Ltd170,931$333.3K0.0%No change
Goldman Sachs Group Inc161,321$314.6K0.0%+48,858
Alps Advisors Inc117,096$228.3K0.0%New
Dimensional Fund Advisors LP116,341$226.9K0.0%−29,981
Jpmorgan Chase & Co81,556$161.5K0.0%+24,067
Geode Capital Management, LLC68,849$134.3K0.0%No change
Headlands Technologies LLC65,183$127.1K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28